CD19-Targeted Nanodelivery of Doxorubicin Enhances Therapeutic Efficacy in B-Cell Acute Lymphoblastic Leukemia

Molecular Pharmaceutics - United States
doi 10.1021/acs.molpharmaceut.5b00071
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Chemical Society (ACS)

Related search

CD19 CAR-Targeted T Cells Induce Long-Term Remission and B Cell Aplasia in an Immunocompetent Mouse Model of B Cell Acute Lymphoblastic Leukemia

PLoS ONE
Multidisciplinary
2013English

Inhibition of Notch Signaling Enhances Chemosensitivity in B Cell Precursor Acute Lymphoblastic Leukemia.

Cancer Research
Cancer ResearchOncology
2018English

P53-Mdm2 Pathway: Evidences for a New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia

Frontiers in Pharmacology
Pharmacology
2016English

Potent Anti-Leukemia Activities of Humanized CD19-targeted CAR-T Cells in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

American Journal of Hematology
Hematology
2018English

Heterogeneity of Surface CD19 and CD22 Expression in B Lymphoblastic Leukemia

American Journal of Hematology
Hematology
2018English

Prognostic Factors of Adults B-Cell Acute Lymphoblastic Leukemia

Sohag Medical Journal
2017English

Role of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia

Memo - Magazine of European Medical Oncology
OncologyHematology
2019English

Immunotoxins Against CD19 and CD22 Are Effective in Killing Precursor-B Acute Lymphoblastic Leukemia Cells in Vitro

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2000English

Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients

Biology of Blood and Marrow Transplantation
TransplantationHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy